Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
About this item
Full title
Author / Creator
Publisher
Waltham, MA: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
Waltham, MA: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In this trial, teriflunomide reduced annualized relapse rates and disability progression over 108 weeks of treatment in patients with relapsing MS, although diarrhea, nausea, hair thinning, and abnormalities in alanine aminotransferase levels were reported.
Teriflunomide, the active metabolite of leflunomide, is being investigated as a new oral...
Alternative Titles
Full title
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_swepub_primary_oai_swepub_ki_se_541383
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_swepub_primary_oai_swepub_ki_se_541383
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1014656
